

# SIMRAN FARMS LIMITED

(CIN L01222MP1984PLC002627)

Regd. Office: 1-B, Vikas Rekha Complex, Khatiwala Tank, Tower Square, Indore (M.P) 452001

Phone: 0731-4255900, Fax: 0731-4255949; Web: www.simranfarms.com, Email: compliance@simranfarms.com

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2017

Rs. in Lakhs (except Earning Per Share)

Particulars	Quarter Ended			Year Ended
	30-Jun-17	30-Jun-16	31-Mar-17	31-Mar-17
	Unaudited	Unaudited	Audited	Audited
<b>1. Income</b>				
(a) Revenue from Operations	10795.38	11232.86	9767.96	41002.94
(b) Other Income	9.45	5.37	6.15	21.54
<b>Total Income from Operations (net)</b>	<b>10804.83</b>	<b>11238.23</b>	<b>9774.11</b>	<b>41024.48</b>
<b>2. Expenses</b>				
(a) Consumption of raw materials	8703.35	8861.68	6612.48	32844.24
(b) Changes in inventories of finished goods	0.00	0.00	0.00	0.00
(c) Employees benefits expenses	330.41	303.16	323.44	1188.15
(d) Depreciation	51.39	55.32	32.12	200.03
(e) Finance Cost	101.21	186.70	136.02	608.72
(f) Other expenses	1265.11	1465.45	1475.76	6038.16
<b>Total Expenses</b>	<b>10451.47</b>	<b>10872.31</b>	<b>8579.82</b>	<b>40879.30</b>
<b>3. Profit/(Loss) from Operations before exceptional and extra ordinary items and tax ( 1-2 )</b>	<b>353.36</b>	<b>365.92</b>	<b>1194.29</b>	<b>145.18</b>
4. Exceptional items	0	0	0	0
<b>5. Profit/(Loss) from Operations before extra ordinary items and tax ( 1-2 )</b>	<b>353.36</b>	<b>365.92</b>	<b>1194.29</b>	<b>145.18</b>
6. Extraordinary items	0	0	0	0
<b>7. Profit/(Loss) before tax (3-4)</b>	<b>353.36</b>	<b>365.92</b>	<b>1194.29</b>	<b>145.18</b>
8. Tax expense				
i) Current tax	72.04	74.60	56.00	29.60
ii) Deferred tax	0.88	5.52	0.00	26.40
iii) MAT credit	0.00	0.00	0.00	(5.46)
Total tax expenses	72.92	80.12	56.00	50.54
<b>9. Net Profit/ (Loss) for the period</b>	<b>280.44</b>	<b>285.80</b>	<b>1138.29</b>	<b>94.64</b>
10. Other comprehensive income	0.00	0.00	0.00	0.00
<b>11 Total comprehensive income for the period</b>	<b>280.44</b>	<b>285.80</b>	<b>1138.29</b>	<b>94.64</b>
12. Paid up Equity Share Capital (Face Value of the Shares of Rs. 10/-)	379.17	379.17	379.17	379.17
13. Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				1335.19
14. Earnings Per Share (EPS) ( of Rs..10 each)				
Basic	7.40	7.54	30.02	2.50
Diluted	7.40	7.54	30.02	2.50


Note:

1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 13th September 2017.

2. The company has adopted Indian Accounting Standard (IND-AS) from 1st April, 2017 and accordingly these financial results have been prepared in accordance with the IND- AS prescribed under section 133 of the Companies Act, 2013. Consequently, the results for the quarter ended on 30th June, 2016 have been restated to comply with IND-AS. Reconciliation of Net Profit reported under previous Indian GAAP and restated now under IND AS is as under :

Rs. in Lakhs

Particulars	Quarter Ended 30/06/2016
Profit after tax (PAT) as per previous Indian GAAP	276.96
Effect of Fair valuation of Consumable Biological Assets	16.96
Effect of accounting of Loans at amortised cost	(2.60)
Recognition of deferred tax as per IND AS 12	(5.52)
<b>Profit after Tax(PAT) as per Ind AS</b>	
Other Comprehensive Income	-
<b>Total Comprehensive Income as reported under IND AS</b>	<b>285.80</b>



3. Under Indian GAAP, there was no bifurcation between inventories and biological assets and both were valued at cost or net realisable value whichever is lower. Under IND AS, consumable biological assets are measured at fair value less costs to sell at each reporting date.
4. The "Limited Review" of the financial result for the quarter ended 30th June, 2017 pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors of the company. The figures relating to quarter ended 30th June, 2016 as adjusted for the differences in the accounting principles adopted by the company on transition to IND AS have not been subjected to Limited Review or Audit.
5. The company is in the process of obtaining information from the valuer regarding remeasurement of its defined benefit obligation as per IND AS 19. The company will remeasure its defined benefit obligation in upcoming quarter ended 30th September, 2017.
6. The Company has been primarily engaged in Poultry Breeding & Farming activities only. As such, there is no identifiable operating segment, hence there is nothing to disclose under IND AS - 108 'Operating Segment'.
7. The aforesaid Unaudited financial Result will be uploaded on the Company's website [www.simranfarms.com](http://www.simranfarms.com) and will also be available on the website of the BSE Limited [www.bseindia.com](http://www.bseindia.com) for the benefit of shareholders and investors.
8. The above standalone results for the quarter ended on 30th June, 2017 does not include the result of its subsidiary company i.e Puregene Biotech Limited
9. The figure of quarter ended on 31.03.2017 are the balancing figures.

Place : INDORE  
Date : 13th September 2017



FOR SIMRAN FARMS LIMITED

A handwritten signature in black ink, appearing to read "Harender".

(H.S. Bhatia)  
Managing Director  
DIN: 00509426



## KHANDELWAL KAKANI & COMPANY

CHARTERED ACCOUNTANTS

8, Johari Palace, First Floor, 51 M. G. Road, INDORE - 452 001

Phone : 0731-2518269, 2529539 Fax : 0731-4042019

E-mail : kkc@cakhandelwalkakani.com • kkc\_indore@rediffmail.com

### Limited Review Report for the quarter ended 30<sup>th</sup> June, 2017

To,  
The Board of Directors,  
**Simran Farms Ltd.**  
1-B Vikash Rekha Complex,  
Near Tower Chouraha,  
Indore (M.P.)

We have reviewed the accompanying statements of Standalone unaudited financial results of Simran Farms Ltd. for the quarter ended 30th June, 2017 attached herewith. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Further the management is also responsible to ensure that the accounting policies used in the preparation of this statement are consistent with those used in the preparation of the company's opening unaudited balance sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We draw attention to Note 5 to the statement which states that the company has not remeasured its defined benefit obligation as per IND AS -19 for want of Information from its valuer. The impact of this non compliance is presently not determinable.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('IND AS')



prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For: Khandelwal Kakani and Co.  
Chartered Accountants  
FRN: 001311C



A handwritten signature in black ink, appearing to read 'Santosh Deshmukh', written over a horizontal line.

CA Santosh Deshmukh  
Partner  
M.No: 071011

Place: Indore  
Date: 13 September, 2017